• Cytek Biosciences Inc CTKB.OQ reported quarterly adjusted earnings of 7 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 4 cents. The mean expectation of six analysts for the quarter was for earnings of 5 cents per share. Wall Street expected results to range from 4 cents to 7 cents per share.

• Revenue fell 1.3% to $57.48 million from a year ago; analysts expected $59.38 million.

• Cytek Biosciences Inc's reported EPS for the quarter was 7 cents​.

• The company reported quarterly net income of $9.64 million.

• Cytek Biosciences Inc shares had fallen by 23.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 7.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the advanced medical equipment & technology peer group is "hold."

Wall Street's median 12-month price target for Cytek Biosciences Inc is $8.50

This summary was machine generated from LSEG data February 28 at 04:31 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)